Approval · Notice of Compliance 3392 · 2003

REVIA: Notice of Compliance 3392

Issued May 13, 2003

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 3392
Date: May 13, 2003
Company: Duramed Pharmaceuticals, Inc. Subsidiary Of Barr Laboratories, Inc.
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Therapeutic class: Opioid antagonist

Products in this notice

Brand	DIN	Status today
REVIA	02213826	Marketed

Medicinal ingredients

NALTREXONE HYDROCHLORIDE 50 MG per TAB